New email dellery1@gmail.com
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looking better!
Today's Top tickerspy Indexes:
Uranium Stocks (up 3.3%, see graph): With the dollar down, commodity stocks are showing strength, with uranium names leading the way. The bet right now in this segment is that the market is discounting this sector too much in the wake of the nuclear disaster in Japan, and that uranium demand will recover more quickly than expected. Uranium Energy (AMEX: UEC - News) and Uranium Resources (NASDAQ: URRE - News) are among the top movers today.
Thanks Manti!
Im digging in.
What does UCRP do in Laymen," Realperson", terms?
I dont understand what all those words mean
""We Are Your Value Added Agency""
In heart of New York City's Union Square, is a dynamic lifestyle agency with a strong foundation of multidisciplinary expertise.
Union Square Agency takes the traditional definition of "agency" to another level, offering a contemporary set of values to entertainment-centric properties and
programs.
A nimble shop built on a culture of collaboration, Union Square delivers truly integrated, innovative and unparalleled 360 degree solutions from idea conceptualization to fulfillment.
Our clients come to us with a challenge and we deliver above and beyond what they thought was possible. We weave various lifestyle elements into each project for truly integrated solutions. We assist in maximizing awareness through activations that enable brands to leave meaningful imprints on consumers, increasing brand loyalty and sales. In addition, our media robust intellectual properties are unique platforms that offer tremendous impact and value.
Yes its not just CXZ the whole uranium sector was hit.
Compare the CXZ chart to charts of URG, DNN, URZ, or URRE they all went way down after Japan's disaster.
The world demand for uranium continues, investor sentiment will resume eventually.
Dry Bulkers Brace for Brutal Impact
http://www.fool.com/investing/general/2011/05/10/dry-bulkers-brace-for-brutal-impact.aspx
Christopher Barker
May 10, 2011
Ever since the very first wave of destruction that tossed a buoyant dry bulk shipping industry to its tipping point back in 2008, always-opportunistic Foolish investors have maintained a disciplined vigil for signs of calmer seas on the horizon.
In no uncertain terms, unfortunately, Diana Shipping (NYSE: DSX ) resurrected a troubling, two-year-old warning during its first-quarter conference call last week. Fools may recall that Diana's president, Anastasios Margaronis, issued an alert to investors in May of 2009 that stated "the challenge for most shipping companies will be to survive over the next two years or so."
According to Mr. Margaronis' seasoned perspective, it seems, surprisingly strong business conditions in 2010 forestalled some of the more frightful market scenarios that nonetheless remained on the company's long-term radar screen. Citing newly revised global economic forecasts and shipping industry projections -- and a persistently excessive slate of new vessel construction overhanging the battered industry -- he offers the somber reminder that "the inevitable cannot be indefinitely postponed".
Dry bulk's unavoidable days of reckoning
Indeed, atop the already acutely oversupplied condition of the dry bulk industry today -- which is reflected in the 38% sequential decline in the average daily charter rate realized by spot-market tracker Baltic Trading (NYSE: BALT ) -- new vessels presently on order would add an astounding 47.3% to the size of the current global fleet. Even accounting for projections of delayed and canceled orders, the Capesize fleet is expected to expand by 14% in 2011, and the Panamax fleet may grow by 12%. The corresponding forecast for only 5% growth in global demand for dry bulk haulage, meanwhile, is nowhere near sufficient to absorb the projected capacity increase in an orderly manner.
I have been concerned about the long-term survival prospects of heavily indebted dry bulk shippers for some time; though admittedly, as time passed, and none of the U.S.-traded shippers that I follow sank to the ocean floor, I grew increasingly complacent about those failure risks. Sure, a pair of defaults by major Korean shipping lines sent shockwaves through the industry, but they caused no semblance of the "wave of destruction for banks to rival the subprime crisis" that Margaronis warned of in 2009.
Following Mr. Margaronis' pointed reminder, however, this Fool's complacency has been abruptly obliterated, and replaced by reactivated scrutiny of the sector's leading failure risks. Within that context, Navios Maritime's (NYSE: NM ) practice of mitigating counterparty risk -- by insuring charter contracts -- becomes an important factor for Fools to consider. When Korea Line entered receivership last February, that insurance spared Navios from the lasting damage that competitor Eagle Bulk Shipping (Nasdaq: EGLE ) has suffered. Eagle turned in a $5.8 million net loss for the first quarter of 2011.
A rate collapse takes its toll
Under the intensifying strain of painfully weak charter rates, Eagle was not the sole carrier to post a loss for the first quarter. Excel Maritime Carriers (NYSE: EXM ) lost a million bucks as its realized average daily charter rate slipped 20% from the prior-year period. The aforementioned Baltic Trading lost $1.7 million. Genco Shipping & Trading (NYSE: GNK ) managed to eke a $13.4 million profit, but only because the company added 13 new vessels the fleet. Without that substantial expansion of scale, the 37% decline in Genco's average charter rate would have decimated profitability.
Diana Shipping benefited from some counter-cyclical fleet expansion of its own, but the savvy operator experienced only a 1% decline in its average daily charter rate. At $31,592, that average stands among the best in the industry, and the vast majority of Diana's fleet remains locked into long-term contracts at rates well above the prevailing spot market. In addition, Diana achieved an 11% drop in vessel operating expenses for the first quarter. Not only did Diana record a profit during a quarter marked by crumbling market fundamentals, but the company managed to improve upon the prior-year mark by 15% to take home $33.1 million.
Diana Shipping continues to shine as the ultimate relative safe haven amid a sea of dry bulk uncertainty, due to a solid relative profitability profile, an astute executive team with its finger correctly on the pulse of the ongoing dry bulk industry crisis, and a pristine balance sheet that positions the company for transformative, opportunistic growth near the eventual bottom of the business cycle. As a long-term investor, patiently awaiting the inevitable reversal of this extended downward spiral, I routinely feel as though I am catching a falling knife. With steadfast positions in Diana Shipping and Baltic Trading, however -- plus a miniscule, ultra-high-risk, and ultra-speculative bet on a miraculous turnaround for DryShips (Nasdaq: DRYS ) -- I trust the resulting wounds will prove limited in both scale and duration.
sounds like sound advice!
Good for you Vic!
Isn't that the Reel Time Barry company?
Rexahn Pharma Reports Two-Thirds of Patients Enrolled in Key Clinical Trial
http://seekingalpha.com/article/268349-rexahn-pharma-reports-two-thirds-of-patients-enrolled-in-key-clinical-trial?source=yahoo
I sold all my KERX at 4.92, bought at 3.92. Perhaps I will buy back on a dip.
Looks like someone knew yesterday and sold into the good news.
Rat Bastards
This will do it every time.
Keryx Biopharmaceuticals, Inc. Prices Common Stock Offering
NEW YORK, May 4, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease ("Keryx" or the "Company"), today announced the pricing of an underwritten registered offering of 7,021,277 shares of its common stock at a price of $4.70 per share.
The aggregate gross proceeds, before commissions and expenses, of the offering will be approximately $33.0 million. All of the shares are being sold by the Company. The offering is expected to close on May 9, 2011, subject to customary closing conditions.
Stifel Nicolaus Weisel is acting as the sole book-running manager in this offering with Oppenheimer & Co. Inc., Roth Capital Partners, Rodman & Renshaw, LLC, Brean Murray, Carret & Co. and Ladenburg Thalmann & Co. Inc. acting as co-managers, and JMP Securities LLC acting as financial advisor to the Company.
The shares will be issued pursuant to a shelf registration statement on Form S-3 previously filed with and declared effective by the Securities and Exchange Commission. The Company also will file with the Securities and Exchange Commission a prospectus supplement with respect to the offering.
This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the prospectus supplement and accompanying prospectus may be obtained, when available, by mail from: Stifel, Nicolaus & Company, Incorporated, Equity Syndicate Department, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by phone at (415) 364-2720.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the Food and Drug Administration (FDA). Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.
KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com
SOURCE Keryx Biopharmaceuticals, Inc.
________________________________________________________________
http://www.prnewswire.com/news-releases/keryx-biopharmaceuticals-inc-prices-common-stock-offering-121242314.html
KERX
Howdy Sherm
I was in Ohio (Put-In-Bay) the week before last enjoying your weather and eating walleye and Ballreich's potato chips
KERX pullback?
http://buyersstrike.wordpress.com/2011/05/02/shane-whittle-canadian-rude-boy-jamn-bgbr-etc/
Jammin Java Corp (JAMN):
Market Cap as of May 2, 2011: 207mm
Last 12 months sales: 0
Sales since inception: 0
Cash as of last filing: 0
So what does a member of the Marley family, a notorious Canadian stock promoter, a company that is little more than a shell, a late 10K, and a string of unusual transactions all have in common? Jammin Java (JAMN), which closed today at $3.00.
JAMN has been an amazingly popular stock recently, having zoomed from 10c in June of 2010 to today’s $3.00. But what has really changed from when it was an overpriced piece of reverse merger junk at only 10c?
JAMN started life in 2004 as a Nevada based shell called Global Electronic Recovery Corp (GERV). In February 2008 the GERV shell merged with a private company called Marley Coffee, Inc. to become Marley Coffee and the ticker was changed to MYCF. From the moment of the merger until the last reported quarter total revenues have been an astonishing zero. In September 2009 the name of the company changed yet again to Jammin Java (JAMN). Signing the merger forms submitted to the State of Nevada to create this monstrosity was Canadian stock promoter Shane Whittle.
Shane is probably best known as one of the prime movers behind Big Bear Mining (BGBR). Big Bear, which had been virtually dormant since first gaining a listing in 2006, had a stunning rise, quite reminiscent of JAMN, in late April and early May of last year. BGBR went from 3/10ths of a cent (yes, .003) in February, 2010 to $1.75 at its peak in early April, 2010. BGBR shares trade for a whopping $0.075 today.
Read more about Big Bear in the these pieces by Melissa Davis here, here, and here. Read more about Shane in this great piece by David Baines, here. In addition to being a Marley fan, Shane might also be a fan of 80s hair metal act White Lion. When not busy as the CEO of JAMN he runs a Vancouver outfit called White Lion Capital.
As Davis and Baines point out, JAMN shares more than just Shane with BGBR. Both firms are run out of offices in Los Angeles, and both have the same auditor, LBB & Associates, LLP. LBB is not ashamed to trumpet its speciality in Reverse Mergers right on its home page. Another Shane venture, the now delisted, Southern California based, Interactive Television Networks (ITTV) also used LBB & Associates. Here is what the PCAOB had to say about LBB during a routine inspection. Perhaps the most interesting part of the report is this tidbit:
The inspection team identified what it considered to be audit deficiencies. The deficiencies identified in one of the audits reviewed included a deficiency of such significance that it appeared to the inspection team that the Firm did not obtain sufficient competent evidential matter to support its opinion on the issuer’s financial statements. That deficiency was the failure to perform sufficient procedures to determine the appropriateness of an issuer’s accounting for a participation right granted to a lender in a financing arrangement.
Shane is also on the board of Canadian shell Big North Capital, Inc. (NRT/P) which, at a recent 12c per share, sports a mighty market cap of just about $500k Canadian.
Though no longer an officer nor on the board of Global Industries (GBLS), a Wilshire Blvd, LA based 30c pink sheet special, Shane holds 23.2% of the shares. Jack and Helen Whittle of North Vancouver, BC, presumably Shane’s parents, hold an additional 11%. GBLS‘s auditor? You guessed it, LBB & Associates.
The Whittle family, including Nicole Whittle, all show up as selling shareholders in Black Hawk Explorations (BHWX) SB-2 from 2006. BHWX, another LA based pink sheet piece of junk, now trades for 9c a share. With a market cap under $6mm, what firm could you get to audit such a fine company like BHWX? Assuming J Crane & Co. was too busy, why LBB & Associates of course.
Another time we can dive further into the ridiculousness of the JAMN promotion, and explore the common lawyer and transfer agent used by the Whittle stable of firms, but for now, it is safe to say that not only is coffee not generally considered ITAL by strict Rastafari, but JAMN shares sure don’t seem IRIE.
The content contained in this blog represents only the opinions of the author. The author may hold either long or short positions in securities of various companies discussed in the blog. This commentary in no way constitutes investment advice, and should never be relied on in making an investment decision, ever. This blog is not a solicitation of business: all inquiries will be ignored. The content herein is intended solely for the entertainment of the reader, and the author.
Perhaps then JBII will move off the Pink sheets and become a real company. Pink sheets in the end always go bust after making money for their promoters and screwing the believers who drink the Kool Aide. I hope JBII is the exception that proves the rule. No wealth is created in pink sheet or ponzi schemes, money is simply transfered from one person to the other.
KERX Moving up AH 5.60
Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
Date : 04/28/2011 @ 4:00PM
Source : PR Newswire
Stock : Keryx Biopharmaceuticals, Inc. (MM) (KERX)
http://ih.advfn.com/p.php?pid=nmona&article=47463060
Keryx Biopharmaceuticals (Nasdaq: KERX) today announced the final dataset from the Phase 3 short-term clinical trial of Zerenex™ (ferric citrate) for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. The Zerenex data was presented earlier today at the National Kidney Foundation Spring Clinical Meetings being held in Las Vegas, Nevada, in an oral presentation by David S. Goldfarb, M.D., Clinical Chief of Nephrology, NYU Langone Medical Center, Professor of Medicine & Physiology, NYU School of Medicine. On November 30, 2010, the Company issued a press release announcing positive top-line results from this Phase 3 short-term study.
Phase 3 short-term study design
This Phase 3 study was a multicenter, randomized, open-label trial with a two-week washout period, following which patients were randomized 1:1:1 to receive a fixed dose of Zerenex of either 1 gram, 6 grams or 8 grams per day for a treatment period of 28 days. Zerenex was administered using a 1 gram oral caplet formulation, hence, the fixed-dose arms of 1 gram, 6 grams and 8 grams per day represent 1, 6 and 8 pills per day, respectively.
One hundred fifty-one dialysis patients were enrolled into the study. The Intent-to-Treat (ITT) group included 146 patients, representing all patients who took at least one dose of Zerenex and provided a Baseline (at the end of washout) and at least one post-Baseline efficacy assessment. Efficacy assessments were taken weekly starting at Baseline and subsequently at days 7, 14, 21 and 28.
EFFICACY DATA ANALYSES
The primary endpoint of the study was to determine whether there was a dose response in the change in serum phosphorus from Baseline to Day 28 in the ITT group, using a regression analysis to evaluate this objective.
The study met the primary endpoint, with the regression analysis indicating a highly statistically significant dose response (p<0.0001).
http://www.finanznachrichten.de/nachrichten-2011-04/20076999-keryx-biopharmaceuticals-announces-positive-final-data-from-zerenex-short-term-phase-3-study-008.htm
Additional highlights from Dr. Goldfarb''s presentation on Zerenex are as follows:
* Statistically significant dose response increase in serum bicarbonate suggests potential to address metabolic acidosis
* Statistically significant dose response reduction in calcium x phosphorus product
* Modest upward trends in Ferritin and TSAT in 6 grams/day and 8 grams/day dose groups further supports theory that Zerenex could reduce the need for intravenous iron and erythropoiesis-stimulating agent (ESA) use
* Zerenex appeared to be safe and well-tolerated in the study
* GI adverse events were mostly mild and transient in nature
* No SAEs were deemed to be drug-related by the Data Safety Monitoring Committee
Dr. Goldfarb concluded that Zerenex has the potential to become a viable alternative to the currently approved phosphate binders used to treat ESRD patients.
Ron Bentsur, Chief Executive Officer of Keryx, stated, "We are encouraged by the final efficacy and safety data from the Phase 3 short term study presented earlier today, which confirm the top-line data previously reported." Â Mr. Bentsur continued, "We thank Dr. Goldfarb for his time and effort in preparing for and delivering this morning''s presentation."
In accordance with the Company''s Special Protocol Assessment (SPA) agreement with the FDA, the Phase 3 clinical program for Zerenex consists of two clinical studies, the completed short-term study, and a long-term safety and efficacy study that is currently ongoing.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with approved therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease on dialysis is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.
Cautionary Statement
Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for Zerenex'' (ferric citrate) may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability, and our Japanese partner''s ability, to successfully and cost-effectively complete clinical trials for Zerenex (ferric citrate); uncertainties related to the regulatory process; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.
KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com
SOURCE Keryx Biopharmaceuticals, Inc.
The decision to sell a stock you've researched and followed for months or years is never easy. If you fall in love with your stock holdings, you risk becoming vulnerable to confirmation bias -- listening only to information that supports your theories, and rejecting any contradictions.
Three largest online poker sites indicted and shut down by FBI
The founders of the three largest online poker sites were indicted by the FBI on Friday in what could serve as a death blow to the thriving industry.
Eleven executives at PokerStars, Full Tilt Poker, Absolute Poker and a number of their affiliates were charged with bank fraud and money laundering in an indictment unsealed in a Manhattan court. Two of the defendants were arrested on Friday morning in Utah and Nevada. Federal agents are searching for the others.
Prosecutors are seeking to immediately shut down the sites and to eventually send the executives to jail and to recover $3 billion from the companies. By Friday afternoon Full Tilt Poker’s site displayed a message explaining that “this domain name has been seized by the F.B.I. pursuant to an Arrest Warrant.”
The online gambling industry has taken off over the last decade, drawing an estimated 15 million Americans to bet online.
In 2006 Congress passed a law curtailing online gambling. Most of the leading sites found ways to work around the law, but prosecutors allege that in doing so they broke the law.
“These defendants concocted an elaborate criminal fraud scheme, alternately tricking some U.S. banks and effectively bribing others to assure the continued flow of billions in illegal gambling profits,” Preet Bharara, the U.S. attorney in Manhattan, said in a statement.
Poker fans took to Twitter in droves, worried about the money in their online gaming accounts, fretting that online poker's days were at an end.
"Well the good news is I think I only had about $300 left on the online poker sites overall," tweeted Jimi Schindler of Madison, Wis. "Maybe I'll see that money?!!?"
http://latimesblogs.latimes.com/money_co/2011/04/three-largest-online-poker-sites-indicted-and-shut-down-by-fbi.html
3 Potential Takeover Targets and How to Profit
Tyco International Ltd. (TYC), Intersil Corporation (ISIL), and Keryx Biopharmaceuticals (KERX) are three potential takeover targets ripe for profit-taking in 2011.
http://seekingalpha.com/article/263384-3-potential-takeover-targets-and-how-to-profit?source=yahoo
Tyco Could be Worth $67.00+ in a Takeover
Tyco International Ltd. (TYC), a diversified company with numerous segments targeting many industries, could be worth $67+ in a takeover transaction, according to FBR Capital. The analyst suggested that the company’s sum-of-parts valuation was around $58-62 per share and that a 15-20% change of control premium could result in a $67.00 per share or higher takeover offer.
The prediction comes shortly after rumors surfaced that Schneider Electric sent a letter to the company’s board of directors outlining its interest in buying the company. Reports from The Telegraph indicated that Schneider is believed to have hired JP Morgan and Merrill Lynch to advise it on a bid, while Goldman Sachs is reportedly working for Tyco’s board.
Intersil Seen as Takeover Candidate after TI Deal
Intersil Corporation (ISIL), a developer of high-performance analog integrated circuits for four different markets, has been seen as a strong potential takeover candidate after Texas Instruments (TXN) purchased National Semiconductor earlier this year. With the deal occurring at a 78% premium to market price, there has been optimism that more semiconductor deals may be on the way.
According to Needham analysts, the Texas Instruments acquisition occurred at a dramatically higher price than most investors expected, while Intersil is a smaller version of what National Semiconductor was before the takeover. Often times, competitors within the industry look to bulk up their own size after acquisitions like these, and the company appears to be a great strategic fit.
Keryx Could Be a Target with Two Late-Stage Drugs
Keryx Biopharmaceuticals (KERX), a biopharmaceutical company focused on the treatment of life-threatening diseases, represents a solid takeover target within the M&A-heavy pharmaceutical industry. With patent expirations on many blockbuster drugs for giants like Pfizer Inc. (PFE) and Merck & Co. Inc. (MRK), there are many companies looking for promising new drugs for their pipelines.
Over the past year, the biopharmaceutical company has moved both of its compounds, KRX-0401 and Zerenex, into Phase III development under an SPA with the FDA. The stock jumped higher after the firm released positive Phase III data from its Zerenex clinical trials, while expected results from its KRX-0401 metastatic colorectal study could provide a further catalyst later this year.
How to Profit from Potential Takeovers
The first step in profiting from potential takeovers is determining the likelihood of the takeover and identifying the market’s sentiment. Often times, this is easiest by watching the company’s options trading activity. Implied volatility (the price of an at-the-money straddle) can tell you when the market is expecting a big jump; looking at the volume versus open interest can tell you where action is happening; and, looking at whether the price is hitting the bid or ask can tell you if it’s buying or selling pressure.
The second step in profiting is then determining how to take advantage of a price jump. If the options have become too expensive from expectations, buying stock on margin can provide leverage. Other creative ways to profit may be purchasing call options in rival companies that may experience a jump in share price after such a bid.
And finally, the third step is hedging out some risk of a no-deal by shorting an industry ETF in a pair trading-like strategy. This way, if the stock down due to a market decline, you are making money on the short to offset those declines. But, if the stock rises significantly due to a buyout, you’re making most of the premium, and only losing out on a marginal increase likely in the short position.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
5 Healthcare Stocks That Insiders Are Buying Now
http://seekingalpha.com/article/263061-5-healthcare-stocks-that-insiders-are-buying-now?source=yahoo
Read it once in school and a second time a few years back. Im looking forward to the movies!
DAVE
There is a Famous Dave's BBQ up the road from me. Great place to go if you want a lot of good food at a good price.
Good for them!
as long as they dont receive government welfare like GE etc the companies should be allowed to compensate WTF they want in a free society.
I like the comments under the video
Thats Chelsy Loveit, head sexual dysfunction research assistant
A buy at a buck????
perhaps but I have enough
will wait and see what Tuesday brings
Cool
I hold RNN and KERX
KERX
How high do we go?
more news out
Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting
http://finance.yahoo.com/news/Keryx-Biopharmaceuticals-prnews-2225633524.html?x=0&.v=1
GPL
I remember you buying GPL around 2.50
I have only been watching
We got a live one
looks like a Keith A wannabe making the rounds
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=61149262
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=61058561